SOT Hub

The SOT Hub is an open-access online resource that provides balanced and up-to-date medical education on Solid Organ Transplantation.

[SOT Hub @SOT_Hub]

What is ECP, and how can its immunomodulatory effects be used in SOT rejection prevention?

Read our latest article here: https://t.co/K0UibOW71c

#transplant #OrganTransplant #TransplantMedicine #MedEd #MedNews

[SOT Hub @SOT_Hub]

New publication 📝 UNOS/OPTN contemporary data, published in @LTxJournal, showed deceased donor #LiverTransplant recipients had a 95% lower adjusted mortality risk vs waitlist candidates (HR, 0.05; p < 0.001), with survival benefit emerging at the MELD 3.0 scores of 12–14 and progressively increasing with higher scores.

Learn more about #LiverTransplantation: https://t.co/6Rx5w2FMMM

#transplant #OrganTransplant #TransplantMedicine #MedNews #MedEd

[SOT Hub @SOT_Hub]

New publication 📝 Longitudinal US registry data, published in @TheJHLT, show reduced waitlist mortality and improved post-transplant survival in first-time combined heart–lung transplantation candidates over the last 40 years. Survival 10 years post-transplant improved vs 1985–1996 in adults and children transplanted in 2007–2016 (HR, 0.58; p < 0.001 and HR, 0.52; p = 0.03).

Learn more about cardiothoracic transplantation: https://t.co/D2a9z5GzfH

#HeartTransplant #LungTransplant #transplant #OrganTransplant #TransplantMedicine #MedNews #MedEd

[SOT Hub @SOT_Hub]

Catch up on the latest developments in abdominal transplantation from #ATC2026Boston, with live social media coverage from the SOT Hub:

https://t.co/kFx9LRl4VY

#SolidOrganTransplantation #OrganTransplant #transplant #TransplantMedicine

[SOT Hub @SOT_Hub]

🚨NEWS🚨

@US_FDA approves centralized EVLP device for deceased-donor lung assessment before transplantation in adults with end-stage lung disease.

Read more: https://t.co/DC4fMySlqt

#LungTransplant #transplant #OrganTransplant #TransplantMedicine #MedEd #MedNew

[SOT Hub @SOT_Hub]

Catch up on the latest developments in cardiothoracic transplantation from #ATC2026Boston, with live social media coverage from the SOT Hub:

https://t.co/zxPcBLKCjY

#SolidOrganTransplantation #OrganTransplant #transplant #TransplantMedicine

[SOT Hub @SOT_Hub]

New publication 📝 Consensus guidelines, published in @LTxJournal, recommend standardized postoperative monitoring, VTE prophylaxis, and structured follow-up within 7 days of discharge to maximize living liver donor safety post-hepatectomy.

Learn more about liver transplantation: https://t.co/6Rx5w2FMMM

#LiverTransplant #LivingDonor #transplant #OrganTransplant #TransplantMedicine #MedNews #MedEd

[SOT Hub @SOT_Hub]

🚨 NEWS 🚨

@HealthNYGov approves a blood-based #KidneyTransplant acute rejection test, establishing nationwide access in the US.

Read more: https://t.co/6WxTZZ3wCU

#transplant #OrganTransplant #TransplantMedicine #MedNews #MedEd

[SOT Hub @SOT_Hub]

Read our recent overview of the role of ECP in inducing immune tolerance for SOT rejection prevention: https://t.co/25G61Y1PYX

#transplant #OrganTransplant #TransplantMedicine #MedEd #MedNews

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Tristan Jones shares results from a retrospective TriNetX study evaluating the safety of belatacept in #KidneyTransplant recipients (matched cohorts; n = 3,842 per group).
Belatacept use was associated with higher risks of bacteremia (HR 1.43; p < 0.001), urinary tract infection (HR 1.49; p < 0.001), meningitis (HR 2.46; p < 0.001), pneumocystosis (HR 1.97; p < 0.001), endemic mycoses (HR 1.76; p = 0.001), and invasive mold infection (HR 1.74; p = 0.045) compared with belatacept-free regimens. Belatacept was also associated with increased risks of rejection (HR 2.14; p < 0.001) and all-cause mortality (HR 1.38; p < 0.001).

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Julia Bini Viotti presents findings from a retrospective study evaluating the impact of adenovirus viral load on clinical outcomes in solid organ transplant recipients (N = 36).
Recipients with peak adenovirus viremia ≥10 million copies/mL (n = 12) experienced longer viremia (61 vs 34 days; p = 0.022) and higher rates of acute kidney injury (75% vs 25%; p = 0.010) compared with those with lower viral loads. Each 10-fold increase in peak viral load was associated with a 27% longer duration of viremia (p = 0.044), while higher viral loads were also associated with a trend toward increased mortality.

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress @univmiami

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Alex Zendel discusses findings from a retrospective study evaluating outcomes associated with belatacept- versus tacrolimus-based immunosuppression in adult deceased donor #KidneyTransplant recipients (N = 410).
CMV infection rates and severity were higher among high-risk recipients receiving belatacept compared with tacrolimus, including higher rates of symptomatic CMV (22.7% vs 2.3%; p = 0.008) and CMV-related admissions (16.7% vs 4.7%). In intermediate-risk recipients, belatacept was also associated with higher rates of symptomatic CMV (6.0% vs 0%; p = 0.020) and CMV-related admissions (6.0% vs 0%; p = 0.004).

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Sarah Shalhoub presents findings from a retrospective OPTN database study evaluating the impact of rituximab exposure during transplantation on post-transplant lymphoproliferative disorder (PTLD) in EBV-mismatched (D+/R−) liver transplant recipients (N = 9,721).
PTLD incidence was lower among recipients exposed to rituximab at transplantation than among those who did not receive rituximab (0.798 vs 4.37 cases per 1,000 person-years). In adult recipients, rituximab exposure was independently associated with a 48% reduction in PTLD risk (adjusted HR 0.513). Primary sclerosing cholangitis and rejection within 6 months were associated with increased PTLD risk.

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Emily Eichenberger shares findings from a retrospective observational study comparing the risk of invasive fungal infection (IFI) among kidney transplant recipients receiving de novo belatacept (n = 1,875) or tacrolimus-based immunosuppression (n = 854).
The cumulative incidence of IFI was similar between groups (p = 0.514), with 3-year incidences of 2.4% and 3.7% in the belatacept and tacrolimus cohorts, respectively. Belatacept was not associated with an increased risk of IFI compared with tacrolimus (HR 0.87). Independent risk factors for IFI included age >65 years, high-dose corticosteroid exposure, and CMV reactivation. IFI was associated with a 5-fold increase in mortality risk (HR 5.03).

Follow our live feed for more updates: https://t.co/FJTLuPWMa8

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress @EmoryUniversity

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Keri Lunsford presents interim findings from the continued access phase of the PILOT trial evaluating hypothermic oxygenated machine perfusion (HMP-O₂) in deceased donor liver transplantation with 1-year follow-up (N = 117).
Despite a higher-risk donor profile, including 51% extended criteria donors (ECD), outcomes remained consistent with those observed in the randomized PILOT trial. Early allograft dysfunction (EAD) occurred in 17.9% of all recipients and 16.7% of ECD recipients. One-year patient and graft survival were 93.1% and 92.3%, respectively, with no cases of primary nonfunction reported among the first 180 HMP-O₂ cases. Biliary and vascular complication rates remained low, including a 0.8% rate of non-anastomotic strictures.

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress #LiverTransplant @RutgersU

[SOT Hub @SOT_Hub]

🚨 It's the final day of ATC 2026!.

Don’t miss out — catch up on all our live coverage from the past few days via the SOT Hub congress feed.

Available on our website.

[SOT Hub @SOT_Hub]

📩 Want the latest updates in #SolidOrganTransplantation delivered straight to your inbox?

Sign up to the SOT Hub’s free newsletter to receive trial data, therapy approvals, expert opinions, and more — all in one place.

https://t.co/8cFqyAizS2

#OrganTransplantation #MedEd

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Payaswini Vasanth shares results of a retrospective cohort study evaluating outcomes of a reduced-intensity belatacept regimen in highly sensitized kidney transplant recipients (cPRA ≥98%; n = 81) compared with recipients cPRA <98% (n = 745).
Graft and patient survival remained >95% in both groups, with no significant difference in graft survival (p = 0.35). Rates of Grade ≥1 acute rejection (p = 0.79), CMV viremia ≥1,000 copies/mL (p = 0.37), BK viremia ≥100,000 IU/mL (p = 0.58), and kidney function (mean eGFR 48.8 vs 47.7 mL/min/1.73m²; p = 0.54) were comparable between cohorts.

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress @EmoryUniversity

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Booth Vogel presents findings from a retrospective study comparing outcomes of belatacept-based (n = 341) versus tacrolimus-based (n = 85) maintenance immunosuppression in kidney transplant recipients aged ≥60 years (N = 426).
An early analysis suggested higher 3-year mortality with belatacept compared with tacrolimus (p = 0.040). However, with extended follow-up and comparison to matched SRTR controls, no difference in 5-year patient mortality was observed between belatacept- and tacrolimus-based immunosuppression (p = 0.14 and p = 0.11, respectively). Belatacept was associated with improved long-term kidney function (72 vs 45 mL/min/1.73 m²), although rates of biopsy-proven acute cellular rejection were higher.

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress #KidneyTransplant @EmoryUniversity

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Joseph Leventhal presents long-term outcomes from phase II/III studies of donor hematopoietic stem cell chimerism induction in living donor kidney transplant recipients (N = 40).
Durable chimerism enabling complete immunosuppression withdrawal was achieved in 30/40 patients (75%), with 27/30 developing full donor chimerism. Nineteen patients have remained immunosuppression-free for >10 years, while overall patient survival and death-censored graft survival were 92.5% and 91.9%, respectively. In phase III, all patients achieved engraftment and immunosuppression withdrawal. Grade >1 acute GVHD occurred in 3 patients, all in poorly matched donor-recipient pairs.

Follow our live feed for more updates: https://t.co/FJTLuPWekA

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress @transplantjoe1 @NM_Transplant

[SOT Hub @SOT_Hub]

CONGRESS | #ATC2026Boston | PRESENTATION

Arnaud Del Bello shares findings from a retrospective study evaluating the impact of prolonged low-dose tacrolimus following belatacept during the first year post-transplant (N = 603; ≤1 month, n = 353; 1–3 months, n = 83; ≥3 months, n = 167).
Tacrolimus-belatacept coadministration for ≥3 months was independently associated with a lower risk of biopsy-proven rejection compared with ≤1 month of coadministration (aHR 0.49; p = 0.04). However, prolonged coadministration was associated with a higher risk of infections requiring hospitalization (aHR 1.60; p = 0.01) and opportunistic infections (aHR 2.04; p = 0.01). Prolonged tacrolimus-belatacept coadministration may help reduce rejection risk after belatacept initiation, although this benefit must be balanced against an increased risk of infections.

Follow our live feed for more updates: https://t.co/FJTLuPWekA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#Transplantation #Transplant #OrganTransplant #TransplantMedicine #MedicalCongress